- Home
- LTC vs DNLI Comparison
LTC vs DNLI Comparison
Compare LTC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- DNLI
- Stock Information
- Founded
- LTC 1992
- DNLI 2013
- Country
- LTC United States
- DNLI United States
- Employees
- LTC N/A
- DNLI N/A
- Industry
- LTC Real Estate Investment Trusts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LTC Real Estate
- DNLI Health Care
- Exchange
- LTC Nasdaq
- DNLI Nasdaq
- Market Cap
- LTC 1.7B
- DNLI 1.9B
- IPO Year
- LTC 1992
- DNLI 2017
- Fundamental
- Price
- LTC $35.37
- DNLI $13.24
- Analyst Decision
- LTC Hold
- DNLI Strong Buy
- Analyst Count
- LTC 5
- DNLI 15
- Target Price
- LTC $37.80
- DNLI $33.85
- AVG Volume (30 Days)
- LTC 344.6K
- DNLI 1.3M
- Earning Date
- LTC 05-05-2025
- DNLI 05-06-2025
- Dividend Yield
- LTC 6.44%
- DNLI N/A
- EPS Growth
- LTC 0.36
- DNLI N/A
- EPS
- LTC 1.93
- DNLI N/A
- Revenue
- LTC $202,686,000.00
- DNLI N/A
- Revenue This Year
- LTC N/A
- DNLI N/A
- Revenue Next Year
- LTC $4.41
- DNLI $256.73
- P/E Ratio
- LTC $18.33
- DNLI N/A
- Revenue Growth
- LTC 3.98
- DNLI N/A
- 52 Week Low
- LTC $31.70
- DNLI $10.57
- 52 Week High
- LTC $39.89
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- LTC 49.40
- DNLI 41.80
- Support Level
- LTC $34.97
- DNLI $12.86
- Resistance Level
- LTC $35.86
- DNLI $13.77
- Average True Range (ATR)
- LTC 0.56
- DNLI 0.75
- MACD
- LTC -0.05
- DNLI -0.11
- Stochastic Oscillator
- LTC 37.58
- DNLI 14.07
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.